Sandoz

(IN BRIEF) Sandoz is celebrating 20 years since the approval of Omnitrope, the world’s first biosimilar medicine, which helped establish a new pharmaceutical category and expand patient access to biologic treatments. Since its launch, Omnitrope has generated significant healthcare savings … Read the full press release →

(IN BRIEF) Sandoz has announced a new partnership with Samsung Bioepis to develop and commercialize up to five biosimilar medicines, beginning with a vedolizumab biosimilar targeting inflammatory bowel diseases. The agreement grants Sandoz global commercialization rights in most markets, while … Read the full press release →

(IN BRIEF) Henkel has introduced Teroson MS 949 FR, a new fire-retardant adhesive sealant designed for railcar applications that combines strong performance with improved sustainability and safety characteristics. The primer-less and tin-free material is suitable for sealing interior and exterior … Read the full press release →

(IN BRIEF) The European Commission has approved Ranluspec, a ranibizumab biosimilar developed by Lupin and commercialized by Sandoz, for the treatment of neovascular age-related macular degeneration and several other retinal disorders. The therapy has demonstrated comparable efficacy and safety to … Read the full press release →

(IN BRIEF) Sandoz has joined two new multi-buyer virtual Power Purchase Agreements in Europe under Schneider Electric’s Energize programme, working with suppliers to support new renewable energy projects and expand access to clean electricity. The agreements build on a previous … Read the full press release →